Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Bunov 15 microgram/hour Transdermal patch

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Buprenorphine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Buprenorphine

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for 2. What you need to know before you use Bunov 3. How to use Bunov 4. Possible side effects

What you need to know before you take it

e Bunov Do not use Bunov:

  • if you are allergic to buprenorphine or any of the other ingredients of this medicine (listed in section 6);
  • if you have breathing problems;
  • if you are addicted to drugs;
  • if you are taking a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromide, phenelzine, isocarboxazid, moclobemide and linezolid), or you have taken this type of medicine in the last two weeks;
  • if you suffer from myasthenia gravis (a condition in which the muscles become weak);
  • if you have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating upon stopping taking alcohol.
  • if you have pain which lasts only for a short period or pain after having an operation because of the increased risk of dependence and developing serious breathing problems. If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital if you are currently treated with Bunov transdermal patch to discuss your pain management. Bunov must not be used to treat symptoms associated with drug withdrawal. Warnings and precautions Talk to your prescriber before taking this medicine if you:
  • are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs.
  • have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating, when you have stopped taking alcohol or drugs.
  • f eel you need to use more Bunov to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative pain reliever. Taking this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. Talk to your doctor or pharmacist before using Bunov:
  • if you are treated with antidepressants. The use of these medicines together with Bunov can lead to serotonin syndrome, a potentially life-threatening condition (see "Other medicines and Bunov");
  • if you suffer from seizures, fits or convulsions;
  • if you suffer from a breathing related sleep disorder (sleep apnoea);
  • if you have a severe headache or feel sick due to a head injury or increased pressure in your
  • skull (for instance due to brain disease). This is because the patches may make symptoms worse or hide the extent of a head injury;
  • if you are feeling light-headed or faint;
  • if you have severe liver problems;
  • if you or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction");
  • if you are a smoker;
  • if you have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses;
  • if you have a high temperature, as this may lead to larger quantities of the active ingredient being absorbed into the blood than normal.
  • if you suffer from constipation. Sleep-related breathing disorders Bunov can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. This medicine may cause application site reactions which are usually presented by a mild or moderate skin inflammation, and their typical appearance may include redness, swelling, itching, rash, small blisters, and painful/burning sensation at the application site. Most commonly the cause is skin irritation, and these reactions stop after Bunov are removed. More serious allergic reactions may occur such as blisters with discharge, which may spread outside the application site and may not resolve rapidly after Bunov removal. Chronic allergic reactions may lead to open wounds, bleeding, ulcers, skin discoloration and infections. If you notice any of the above skin reactions, please contact your doctor. This medicine may increase your sensitivity to pain particularly at high doses. Tell your doctor if this happens. A reduction in your dose or a change in your medicine may be necessary. If you have recently had an operation, please speak to your doctor before using these patches. Similar to other opioids, Bunov may affect the normal production of hormones in the body, such as cortisol or sex hormones, particularly if you have taken high doses for long period of time. Children and adolescents Do not give this medicine to children and adolescents below 18 years. Other medicines and Bunov Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines may increase the side effects of Bunov and may sometimes cause very serious reactions. Do not take any other medicines whilst taking Bunov without first talking to your doctor, especially:
  • Anti-depressants such as moclobemide, tranylcypromine, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, doxepine, or trimipramine. These medicines may interact with Bunov and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 38°C. Contact your doctor when experiencing such symptoms.
  • Bunov must not be used together with a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or if you have taken this type of medicine in the last two weeks.
  • If you take some medicines such as phenobarbital or phenytoin (medicines commonly used to treat seizures, fits or convulsions), carbamazepine (a medicine to treat seizures, fits or convulsions and certain pain conditions), or rifampicin (a medicine to treat tuberculosis) the effects of Bunov may be reduced.
  • Bunov may make some people feel drowsy, sick or faint or make them breathe more slowly or weakly. These side effects may be made worse if other medicines that produce the same effects are taken at the same time. These include certain medicines to treat pain, depression, anxiety, psychiatric or mental disorders, medicines to help you sleep, medicines to treat high blood pressure such as clonidine, other opioids (which may be found in painkillers or certain cough mixtures e.g. morphine, dextropropoxyphene, codeine, dextromethorphan, noscapine), antihistamines which make you drowsy, or anaesthetics such as halothane. Concomitant use of Bunov and sedative medicines such as benzodiazepines or related drugs may increase the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However if your doctor does prescribe Bunov together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Bunov with food, drink and alcohol Alcohol may make some of the side effects worse and you may feel unwell if you drink alcohol whilst wearing Bunov. Drinking alcohol whilst using Bunov may also affect your reaction time. Pregnancy, breast-feeding and fertility Do not use Bunov patches if you are pregnant or think you may be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Bunov patches during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Do not use Bunov patches while you are breastfeeding as buprenorphine passes into breast milk and will affect your baby. You should not use Bunov if you are pregnant or are breast-feeding, think you may be pregnant or are planning to have a baby, unless otherwise instructed by your doctor having carefully considered the benefits and risk to both the mother and the child. Ask your doctor or pharmacist for advice before using this medicine. Driving and using machines Bunov may affect your reactions to such an extent that you may not react adequately or quickly enough in the event of unexpected or sudden occurrences. This applies particularly:
  • at the beginning of treatment;
  • if you are taking medicines to treat anxiety or help you sleep;
  • if your dose is increased. Bunov can affect your ability to drive as it may make you sleepy or dizzy.
  • Do not drive while taking this medicine until you know how it affects you.
  • It is an offence to drive if this medicine affects your ability to drive.
  • However, you would not be committing an offence if:
  • The medicine has been prescribed to treat a medical or dental problem and
  • You have taken it according to the instructions given by the prescriber or in the information provided with the medicine and
  • It was not affecting your ability to drive safely Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. If you are affected (e.g. feel dizzy, drowsy or have blurred vision), you should not drive or operate machinery whilst using Bunov, or for 24 hours after removing the patch.

How to take it

Bunov Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Different strengths of Bunov are available. Your doctor will decide which strength of Bunov will suit you best. During treatment, your doctor may change the patch you use to a smaller or larger one if necessary, or tell you to use a combination of up to two patches. Do not cut or divide the patch or use a higher dose than recommended. You should not apply more than two patches at the same time, up to a maximum total dose of 40 micrograms/hour. If you feel that the effect of the Bunov is too weak or too strong, talk to your doctor or pharmacist. Your prescriber should have discussed with you how long the course of patches will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Adults and elderly patients Unless your doctor has told you differently, attach one Bunov patch (as described in detail below) and change it every seventh day, preferably at the same time of day. Your doctor may wish to adjust the dose after 3-7 days until the correct level of pain control has been found. If your doctor has advised you to take other painkillers in addition to the patch, strictly follow the doctor's instructions, otherwise you will not fully benefit from treatment with Bunov. The patch should be worn for 3 full days before increasing the dose, this is when the maximum effect of a given dose is established. Patients with kidney disease/dialysis patients In patients with kidney disease, no change in dose is necessary. Patients with liver disease In patients with liver disease, the effects and period of action of the Bunov may be affected and your doctor will therefore check on you more closely. Patients under 18 years of age Bunov should not be used in patients below the age of 18 years. Method of administration Bunov transdermal patch is for transdermal use. Bunov act through the skin. After application, buprenorphine passes through the skin into the blood. Before applying the transdermal patch

  • Choose an area of non-irritated, intact skin on your upper arm, outer arm, upper chest, upper back or side of the chest. (See illustrations besides). Ask for assistance if you cannot apply the patch yourself.

Upper Arm

OR

Front OR

Back OR

  • The Bunov patch should be applied to a relatively hairless or nearly hairless skin site. If no suitable hair free sites are available the hairs should be cut off with a pair of scissors. Do not shave them off.
  • Avoid skin which is red, irritated or has any other blemishes, for instance large scars.
  • The area of skin you choose must be dry and clean. If necessary, wash it with cold or lukewarm water. Do not use soap, alcohol, oil, lotions or other detergents. After a hot bath or shower, wait until your skin is completely dry and cool. Do not apply lotion, cream or ointment to the chosen area. This might prevent your patch from sticking properly. Applying the transdermal patch
  • Step 1: Each transdermal patch is sealed in a sachet. Just before use, cut the sachet along the sealed edge with scissors. Take out the transdermal patch. Do not use the patch if the sachet seal is broken.
  • Step 2: The sticky side of the transdermal patch is covered with a transparent protective foil. Carefully peel off one part of the foil. Try not to touch the sticky part of the transdermal patch.
  • Step 3: Stick the transdermal patch on to the area of skin you have chosen and remove the remaining foil.
  • Step 4: Press the transdermal patch against your skin with the palm of your hand and count slowly to 30. Make sure that the whole transdermal patch is in contact with your skin, especially at the edges.

Wearing the transdermal patch You should wear the patch for seven days. Provided that you have applied the patch correctly, there is little risk of it coming off. If the edges of the patch begin to peel off, they may be taped down with a suitable skin tape. You may shower, bathe or swim whilst wearing it. Do not expose the patch to extreme heat (e.g. heating pads, electric blanket, heat lamps, sauna, hot tubs, heated water beds, hot water bottle, etc) as this may lead to larger quantities of the active ingredient being absorbed into the blood than normal. External heat may also prevent the patch from sticking properly. If you have a high temperature this may alter the effects of Bunov (see "Warnings and precautions" section above). In the unlikely event that your patch falls off before it needs changing, do not use the same patch again. Stick a new one on straight away (see "Changing the transdermal patch" below).

Changing the transdermal patch

  • Take the old transdermal patch off.
  • Fold it in half with the sticky side inwards.
  • Open and take out a new patch. Use the empty sachet to dispose of the old patch. Now discard the sachet safely.
  • Stick a new transdermal patch on a different appropriate skin site (as described above). You should not apply a new patch to the same site for 3-4 weeks.
  • Remember to change your patch at the same time of day. It is important that you make a note of the time of day. Duration of treatment Your doctor will tell you how long you should be treated with the Bunov. Do not stop treatment without consulting a doctor, because your pain may return and you may feel unwell (see also "If you stop using Bunov" below). If you use more Bunov than you should As soon as you discover that you have used more patches than you should, remove all patches and call your doctor or hospital straight away. People who have taken an overdose may feel very sleepy and sick. They may also have breathing difficulties or lose consciousness and may need emergency treatment in hospital. When seeking medical attention make sure that you take this leaflet and any remaining patches with you to show to the doctor. If you forget to use Bunov Stick a new patch on as soon as you remember. Also make a note of the date, as your usual day of changing may now be different. If you are very late changing your patch, your pain may return. In this case, please contact your doctor. Do not apply additional patches to make up for the forgotten application. If you stop using Bunov Do not suddenly stop using this medicine. If you want to stop using this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you stop using Bunov too soon or you interrupt your treatment your pain may return. If you wish to stop treatment please consult your doctor. They will tell you what can be done and whether you can be treated with other medicines. Some people may have side effects when they have used strong painkillers for a long time and stop using them. The risk of having effects after stopping Bunov is very low. However, if you feel agitated, anxious, nervous or shaky, if you are overactive, have difficulty sleeping or digestive problems, tell your doctor. The pain relieving effect of Bunov is maintained for some time after removal of the patch. You should not start another opioid analgesic (strong painkiller) within 24 hours after removal of the patch. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects that may be associated with Bunov are similar to those seen with other strong painkillers and include difficulty in breathing and low blood pressure. This medicine can cause allergic reactions, although serious allergic reactions are rare. Remove the patch and tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. Drug withdrawal When you stop using Bunov patches you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted? If you notice any of the following signs whilst using Bunov patches, it could be a sign that you have become addicted.

  • You need to use the patches for longer than advised by your prescriber;
  • You feel you need to use more than the recommended dose;
  • You are using the medicine for reasons other than prescribed;
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again. If you notice any of these signs it is important you talk to your prescriber

In patients treated with buprenorphine, the following other side effects have been reported: Very common (may affect more than 1 in 10 people):

  • Headache, dizziness, drowsiness.
  • Constipation, feeling or actually being sick.
  • Itchy skin.
  • Rash, redness, itching, inflammation or swelling of the skin at the application site. Common (may affect up to 1 in 10 people):
  • Loss of appetite.
  • Confusion, depression, anxiety, difficulty in sleeping, nervousness, shaking (tremors).
  • Shortness of breath.
  • Abdominal pain or discomfort, diarrhoea, indigestion, dry mouth.
  • Sweating, rash, skin eruptions.
  • Tiredness, a feeling of unusual weakness, muscle weakness, swelling of hands, ankles or feet. Uncommon (may affect up to 1 in 100 people):
  • Restlessness, agitation, a feeling of extreme happiness, hallucinations, nightmares, decreased sexual drive, aggression.
  • Changes in taste, difficulty in speaking, reduced sensitivity to pain or touch, tingling or numbness.
  • Loss of memory, migraine, fainting, problems with concentration or coordination.
  • Dry eyes, blurred vision.
  • A ringing or buzzing sound in the ears, a feeling of dizziness or spinning.
  • High or low blood pressure, chest pain, fast or irregular heartbeat.
  • Cough, hiccups, wheezing.
  • Wind.
  • Weight loss.
  • Dry skin.
  • Spasms, aches and pains.
  • Difficulty in beginning the flow of urine.
  • Inability to fully empty the bladder.
  • Urinary incontinence.
  • Fever.
  • An increase in accidental injuries (e.g. falls).
  • Withdrawal symptoms such as agitation, anxiousness, sweating or shaking upon stopping using Bunov.
  • Dermatitis contact (skin rash with inflammation which may include burning sensation). If you need to have blood tests remind your doctor that you are using Bunov. This is important because Bunov may change the way your liver works and this could affect the results of some blood tests. Rare (may affect up to 1 in 1,000 people):
  • Angina (chest pain associated with heart disease).
  • Mental disorder.
  • Difficulties with balance.
  • Swelling of the eyelids or face, a reduction in size of the pupils in the eye.
  • Difficulty in breathing, worsening of asthma, over breathing.
  • A feeling of faintness, especially on standing up.
  • Difficulty in swallowing.
  • Local allergic reaction with marked signs of swelling (in such cases treatment should be stopped).
  • Swelling and irritation inside the nose.
  • Decreased erection, sexual dysfunction.
  • A flu like illness.
  • Flushing of the skin.
  • Dehydration. Very rare (may affect up to 1 in 10,000 people):
  • Muscle twitching.
  • Mood swings.
  • Ear pain.
  • Blisters. Not known (frequency cannot be estimated from the available data):
  • Problems with breathing during sleep (sleep apnoea syndrome), see section 2 "Warnings and precautions."
  • Seizures, fits or convulsions.
  • Inflammation of the bowel wall. Symptoms may include fever, vomiting and stomach pain or discomfort.
  • Colicky abdominal pain or discomfort.
  • Feeling detached from oneself.
  • Withdrawal symptoms in babies born to mothers who have been given buprenorphine during pregnancy may include high-pitched crying, irritability and restlessness, shaking (tremor), feeding difficulties, sweating and not putting on weight.
  • Skin discolouration.
  • Dependence and addiction (see section 'How do I know if I am addicted?').

Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any

Possible side effects

not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Bunov Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and sachet after EXP. The expiry date refers to the last day of that month. 15 microgram/h patches: Do not store above 25°C. 30 and 40 microgram/h patches: This medicine does not require any special storage conditions. Do not use the patch if the sachet seal is broken. Used patches must be folded over on themselves with the adhesive layer inwards, and discarded safely. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information What Bunov patches contain

  • The active substance is buprenorphine. Bunov 15 microgram/hour: Each transdermal patch contains 15 mg of buprenorphine in a patch size of 18.75 cm2 and releases 15 micrograms of buprenorphine per hour (over a period of 7 days). Bunov 30 microgram/hour: Each transdermal patch contains 30 mg of buprenorphine in a patch size of 37.5 cm2 and releases 30 micrograms of buprenorphine per hour (over a period of 7 days). Bunov 40 microgram/hour: Each transdermal patch contains 40 mg of buprenorphine in a patch size of 50 cm2 and releases 40 micrograms of buprenorphine per hour (over a period of 7 days).
  • The other ingredients are: Adhesive matrix (containing buprenorphine): povidone, levulinic acid, oleyl oleate, Poly[acrylic acid-co-butylacrylate-co-(2-ethylhexyl)acrylate-covinylacetate], Adhesive matrix (without buprenorphine): Poly[(2-ethylhexyl)acrylate-coglycidylmethacrylate-co-(2-hydroxyethyl)acrylate-co-vinylacetate], Separating foil between adhesive matrices with and without buprenorphine: Polyethylene terephthalate film, Backing foil: polyester, Release liner: Polyethylene terephthalate film, siliconised Blue printing ink. What Bunov look like and contents of the pack Transdermal patch Bunov 15 microgram/hour: Each transdermal patch is beige coloured with rounded corners and is imprinted with "Buprenorphin" and "15 μg/h" Bunov 30 microgram/hour: Each transdermal patch is beige coloured with rounded corners and is imprinted with "Buprenorphin" and "30 μg/h" Bunov 40 microgram/hour: Each transdermal patch is beige coloured with rounded corners and is imprinted with "Buprenorphin" and "40 μg/h" One transdermal patch is sealed in one child-resistant sachet. The patches are available in cartons containing 1, 2, 3, 4, 5, 8, 10 or 12 transdermal patches. Not all pack sizes may be marketed. Marketing Authorisation Holder Glenmark Pharmaceuticals Europe Limited Laxmi House 2B Draycott Avenue Kenton, Middlesex HA3 0BU United Kingdom Manufacturer Labtec GmbH Heykenaukamp 10 21147 Hamburg Germany AdhexPharma 42/44 rue de Longvic 21300 Chenôve France This leaflet was last revised in February 2026

PRODUCT:

Amends:

Brunov/Buprenorphine microgram/h 7 Day transdermal patch 15, 30 & 40 MCG UK GM2355

Cutter Guide Pantone Black

Times New Roman ALL 9 pts body copy (min)

6 9.1.26

Signed (digitally)

Pharmacode XXXX Artwork Sign-off(digitally):

10.6.24 Leaflet (PIL) 480×280 mm

Approval: Internal proof approval

Y

Indesign CS 5

External proof approval Signed (digitally)

Contents of the pack and other information

1. What Bunov is and what it is used for This medicine has been prescribed for you to relieve moderate, long-lasting pain that requires the use of a strong painkiller. It contains buprenorphine which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. Bunov should not be used to relieve acute pain.

Frequently asked questions about Bunov 15 microgram/hour Transdermal patch

How do I take Bunov 15 microgram/hour Transdermal patch?

Bunov 15 microgram/hour Transdermal patch comes as patch containing 15mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Bunov 15 microgram/hour Transdermal patch?

The active substance in Bunov 15 microgram/hour Transdermal patch is buprenorphine.

Are there equivalent medicines to Bunov 15 microgram/hour Transdermal patch?

Medicines with the same active substance, strength and form include: BuTrans 15 microgram/hour transdermal patch, Butec 15 microgram/hour transdermal patch, Rebrikel 15 microgram/hour transdermal patches. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Bunov 15 microgram/hour Transdermal patch, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Bunov 15 microgram/hour Transdermal patch without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Buprenorphine (42 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.

Bunov is not suitable for the treatment of acute pain.

Bunov is indicated in adults.

4.2. Posology and method of administration

Posology

Patients aged 18 years and over:

The lowest Bunov dose (Bunov 5 microgram/hour transdermal patch) should be used as the initial dose. Consideration should be given to the previous opioid history of the patient (see section 4.5) as well as to the current general condition and medical status of the patient.

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with buprenorphine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Titration

During initiation of treatment with Bunov, short-acting supplemental analgesics may be required (see section 4.5) as needed until analgesic efficacy with Bunov is attained.

The dose of Bunov may be titrated upwards as indicated after 3 days, when the maximum effect of a given dose is established. Subsequent dose increases may then be titrated based on the need for supplemental pain relief and the patient's analgesic response to the patch.

To increase the dose, a larger patch should replace the patch that is currently being worn, or a combination of patches should be applied in different places to achieve the desired dose. It is recommended that no more than two patches are applied at the same time, up to a maximum total dose of 40 microgram/hour buprenorphine. A new patch should not be applied to the same skin site for the subsequent 3-4 weeks (see section 5.2). Patients should be carefully and regularly monitored to assess the optimum dose and duration of treatment.

Bunov should be administered every 7th day.

Duration of administration

Bunov should under no circumstances be administered for longer than absolutely necessary. If long-term pain treatment with Bunov is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether and to what extent further treatment is necessary.

Discontinuation

After removal of the patch, buprenorphine serum concentrations decrease gradually and thus the analgesic effect is maintained for a certain amount of time. This should be considered when therapy with Bunov is to be followed by other opioids. As a general rule, a subsequent opioid should not be administered within 24 hours after removal of the patch. At present, only limited information is available on the starting dose of other opioids administered after discontinuation of the transdermal patch (see section 4.5).

Conversion from opioids

Bunov can be used as an alternative to treatment with other opioids. Such patients should be started on the lowest available dose (Bunov 5 microgram/hour transdermal patch) and continue taking short-acting supplemental analgesics (see section 4.5) during titration, as required.

Special populations

Elderly

No dosage adjustment of Bunov is required in elderly patients.

Renal impairment

No special dose adjustment of Bunov is necessary in patients with renal impairment.

Hepatic impairment

Buprenorphine is metabolised in the liver. The intensity and duration of its action may be affected in patients with impaired liver function. Therefore patients with hepatic insufficiency should be carefully monitored during treatment with Bunov.

Patients with severe hepatic impairment may accumulate buprenorphine during Bunov treatment. Consideration of alternate therapy should be considered, and Bunov should be used with caution, if at all, in such patients.

Paediatric population

The safety and efficacy of Bunov in children and adolescents below 18 years of age has not been established. No data are available.

Method of administration

Bunov is for transdermal use.

The patch must not be divided or cut into pieces.

The patch should not be used if the seal is broken.

Patch application

Bunov should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest, but not to any parts of the skin with large scars. Bunov should be applied to a relatively hairless or nearly hairless skin site. If none are available, the hair at the site should be cut with scissors, not shaven.

If the application site must be cleaned, it should be done with clean water only. Soaps, alcohol, oils, lotions or abrasive devices must not be used. The skin must be dry before the patch is applied. Bunov should be applied immediately after removal from the sealed sachet. Following removal of the protective layer, the transdermal patch should be pressed firmly in place with the palm of the hand for approximately 30 seconds, making sure the contact is complete, especially around the edges. If the edges of the patch begin to peel off, the edges may be taped down with suitable skin tape to ensure a 7 day period of wear. The patch should be worn continuously for 7 days. Bathing, showering, or swimming should not affect the patch. If a patch falls off, a new one should be applied and worn for 7 days.

4.3. Contraindications

- hypersensitivity to the active substance or to any of the excipients listed in section 6.1,

- opioid dependent patients and for narcotic withdrawal treatment,

- conditions in which the respiratory center and function are severely impaired or may become so,

- patients who are receiving MAO inhibitors or have taken them within the last two weeks (see section 4.5),

- patients suffering from myasthenia gravis,

- patients suffering from delirium tremens.

4.4. Special warnings and precautions for use

Buprenorphine should be used with particular caution in patients with acute alcohol intoxication, head injury, shock, a reduced level of consciousness of uncertain origin, intracranial lesions or increased intracranial pressure, or in patients with severe hepatic impairment (see section 4.2).

Buprenorphine may lower the seizure threshold in patients with a history of seizure disorder.

Significant respiratory depression has been associated with buprenorphine, particularly by the intravenous route. A number of overdose deaths have occurred when addicts have intravenously abused buprenorphine, usually with benzodiazepines concomitantly. Additional overdose deaths due to ethanol and benzodiazepines in combination with buprenorphine have been reported.

Drug dependence, tolerance and potential for abuse

For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).

Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.

Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.

Patients should be closely monitored for signs of misuse, abuse, or addiction.

The clinical need for analgesic treatment should be reviewed regularly.

Drug withdrawal syndrome

Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with buprenorphine.

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.

Hyperalgesia

Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.

Sleep-related breathing disorders

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.

Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:

Concomitant use of Bunov and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Bunov concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Since CYP3A4 inhibitors may increase concentrations of buprenorphine (see section 4.5), patients already treated with CYP3A4 inhibitors should have their dose of Bunov carefully titrated since a reduced dosage might be sufficient in these patients.

Buprenorphine is not recommended for analgesia in the immediate post-operative period. Do not use for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI) or in other situations characterised by a narrow therapeutic index or a rapidly varying analgesic requirement.

Controlled human and animal studies indicate that buprenorphine has a lower dependence liability than pure agonist analgesics. In humans limited euphorigenic effects have been observed with buprenorphine. This may result in some abuse of the medicinal product and caution should be exercised when prescribing to patients known to have, or suspected of having, a history of drug abuse or alcohol abuse or serious mental illness.

Chronic use of buprenorphine can result in the development of physical dependence. Withdrawal (abstinence syndrome), when it occurs, is generally mild, begins after 2 days and may last up to 2 weeks. Withdrawal symptoms include agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal disorders.

Bunov should not be used at higher doses than recommended.

Patients with fever or exposed to external heat:

While wearing the patch, patients should be advised to avoid exposing the application site to external heat sources, such as heating pads, electric blankets, heat lamps, sauna, hot tubs, and heated water beds, etc., as an increase in absorption of buprenorphine may occur. When treating febrile patients, one should be aware that fever may also increase absorption resulting in increased plasma concentrations of buprenorphine and thereby increased risk of opioid reactions.

Serotonin syndrome

Concomitant administration of Bunov and other serotonergic agents, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5).

If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.

Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.

If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms.

4.5. Interaction with other medicinal products and other forms of interaction

Buprenorphine must not be used concomitantly with MAOIs or in patients who have received MAOIs within the previous two weeks (see section 4.3).

Effect of other active substances on the pharmacokinetics of buprenorphine:

Buprenorphine is primarily metabolised by glucuronidation and to a lesser extent (about 30%) by CYP3A4.

Concomitant treatment with CYP3A4 inhibitors may lead to elevated plasma concentrations with intensified efficacy of buprenorphine.

Studies with the CYP3A4 inhibitor ketoconazole did not produce clinically relevant increases in mean maximum (Cmax) or total (AUC) buprenorphine exposure following buprenorphine with ketoconazole as compared to buprenorphine alone.

The interaction between buprenorphine and CYP3A4 enzyme inducers has not been studied.

Co-administration of buprenorphine and enzyme inducers (e.g. phenobarbital, carbamazepine, phenytoin and rifampicin) could lead to increased clearance which might result in reduced efficacy.

Reductions in hepatic blood flow induced by some general anaesthetics (e.g. halothane) and other medicinal products may result in a decreased rate of hepatic elimination of buprenorphine.

Pharmacodynamic interactions:

Buprenorphine should be used cautiously with:

Other central nervous system depressants: other opioid derivatives (analgesics and antitussives containing e.g. morphine, dextropropoxyphene, codeine, dextromethorphan or noscapine). Certain antidepressants, sedative H1-receptor antagonists, alcohol, anxiolytics, neuroleptics, clonidine and related substances. These combinations increase the CNS depressant activity.

Sedative medicines such as benzodiazepines or related drugs: The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).

Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).

At typical analgesic doses buprenorphine is described to function as a pure mu receptor agonist. In buprenorphine clinical studies subjects receiving full mu agonist opioids (up to 90 mg oral morphine or oral morphine equivalents per day) were transferred to buprenorphine. There were no reports of abstinence syndrome or opioid withdrawal during conversion from entry opioid to buprenorphine (see section 4.4).

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of buprenorphine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.

Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in the neonate even after a short period of administration. Long-term administration of buprenorphine during pregnancy can result in neonatal opioid withdrawal syndrome.

Therefore buprenorphine should not be used during pregnancy and in women of childbearing potential who are not using effective contraception.

Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.

If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.

Breast feeding

Administration to nursing women is not recommended as buprenorphine is secreted in breast milk and may cause respiratory depression in the infant. Studies in rats have shown that buprenorphine may inhibit lactation. Available pharmacodynamic/toxicological data in animals has shown excretion of buprenorphine in milk (see section 5.3). Therefore the use of buprenorphine during lactation should be avoided.

Fertility

No human data on the effect of buprenorphine on fertility are available. In a fertility and early embryonic development study, no effects on reproductive parameters were observed in male or female rats (see section 5.3).

4.7. Effects on ability to drive and use machines

Buprenorphine has a major influence on the ability to drive and use machines. Even when used according to instructions, buprenorphine may affect the patient's reactions to such an extent that road safety and the ability to operate machinery may be impaired. This applies particularly in the beginning of treatment and in conjunction with other centrally acting substances including alcohol, tranquillisers, sedatives and hypnotics. An individual recommendation should be given by the physician. A general restriction is not necessary in cases where a stable dose is used.

Patients who are affected and experience undesirable effects (e.g. dizziness, drowsiness, blurred vision) during treatment initiation or titration to a higher dose should not drive or use machines, for at least 24 hours after the patch has been removed.

4.8. Undesirable effects

Serious adverse reactions that may be associated with buprenorphine therapy in clinical use are similar to those observed with other opioid analgesics, including respiratory depression (especially when used with other CNS depressants) and hypotension (see section 4.4).

The following undesirable effects have occurred:

System organ class

MedDRA

Very common

(≥1/10)

Common

(≥1/100 to <1/10)

Uncommon

(≥1/1000 to <1/100)

Rare

(≥1/10,000 to <1/1000)

Very rare

(<1/10,000)

Not known (cannot be estimated from the available data)

Immune system disorders

Hypersensitivity

Anaphylactic reaction

Anaphylactoid reaction

Metabolism and nutrition disorders

Anorexia

Dehydration

Psychiatric disorders

Confusion,

Depression,

Insomnia,

Nervousness,

Anxiety

Sleep disorder,

Restlessness,

Agitation,

Euphoric mood,

Affect liability,

Hallucinations,

Nightmares,

Decreased libido,

Agression

Psychotic disorder

Drug dependence,

Mood swings

Drug dependence (see section 4.4)

Depersonalisation

Nervous system disorders

Headache,

Dizziness,

Somnolence

Tremor

Sedation,

Dysgeusia,

Dysarthria,

Hypoaesthesia,

Memory impairment,

Migraine,

Syncope,

Abnormal coordination,

Disturbance in attention,

Paraestheia

Balance disorder,

Speech disorder

Involuntary muscle contractions

Convulsions

Eye disorders

Dry eye,

Blurred vision

Visual disturbance,

Eyelid oedema,

Miosis

Ear and labyrinth disorders

Tinnitus,

Vertigo

Ear pain

Cardiac disorders

Palpitations,

Tachycardia

Angina pectoris

Vascular disorders

Hypotension,

Circulatory collapse,

Hypertension,

Flushing

Vasodilatation,

Orthostatic hypotension

Respiratory, thoracic and mediastinal disorders

Dyspnoea

Cough,

Wheezing,

Hiccups

Respiratory depression,

Respiratory failure,

Asthma aggravated,

Hyperventilation,

Rhinitis

Gastrointestinal disorders

Constipation,

Nausea,

Vomiting

Abdominal pain,

Diarrhoea,

Dyspepsia,

Dry mouth

Flatulence

Dysphagia,

Ileus

Diverticulitis

Hepatobiliary disorders

Biliary colic

Skin and subcutaneous tissue disorders

Pruritus,

Erythema

Rash,

Sweating,

Exanthema

Dry skin,

Urticaria,

Dermatitis contact

Face oedema

Pustules,

Vesicles

Application skin discolouration

Musculoskeletal and connective tissue disorders

Muscular weakness

Myalgia,

Muscle spasms

Renal and urinary disorders

Urinary incontinence,

Urinary retention,

Urinary hesitation

Reproductive system and breast disorders

Erectile dysfunction,

Sexual dysfunction

General disorders and administration site conditions

Application site reaction1

Tiredness,

Asthenic conditions,

Peripheral oedema

Fatigue,

Pyrexia,

Rigors,

Oedema,

Drug withdrawal syndrome,

Application site dermatitis*,

Chest pain

Influenza like illness

Drug withdrawal syndrome neonatal

Investigations

Alanine aminotransferase increased,

Weight decreased

Injury, poisoning and procedural complications

Accidental injury,

Fall

* In some cases delayed local allergic reactions occurred with marked signs of inflammation. In such cases treatment with buprenorphine should be terminated.

1 Includes application site erythema, application site oedema, application site pruritus, application site rash.

Buprenorphine has a low risk of physical dependence. After discontinuation of buprenorphine, withdrawal symptoms are unlikely. This may be due to the very slow dissociation of buprenorphine from the opioid receptors and to the gradual decrease of buprenorphine plasma concentrations (usually over a period of 30 hours after removal of the last patch). However, after long-term use of buprenorphine, withdrawal symptoms similar to those occurring during opioid withdrawal, cannot be entirely excluded. These symptoms include agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal disorders.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard.

4.9. Overdose

Symptoms: Symptoms similar to those of other centrally acting analgesics are to be expected. These include respiratory depression, sedation, drowsiness, nausea, vomiting, cardiovascular collapse and marked miosis.

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Treatment: Any patches should be removed from the patient's skin. A patent airway should be established and maintained, respiration should be assisted or controlled as indicated and adequate body temperature and fluid balance should be maintained. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.

A specific opioid antagonist such as naloxone may reverse the effects of buprenorphine, although naloxone may be less effective in reversing the effects of buprenorphine than other µ-opioid agonists. Treatment with continuous intravenous naloxone should begin with the usual doses but high doses may be required.

💬 Ask about this leaflet

Ask anything about Bunov 15 microgram/hour Transdermal patch. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →